
pmid: 35113714
We discovered a highly virulent variant of subtype-B HIV-1 in the Netherlands. One hundred nine individuals with this variant had a 0.54 to 0.74 log 10 increase (i.e., a ~3.5-fold to 5.5-fold increase) in viral load compared with, and exhibited CD4 cell decline twice as fast as, 6604 individuals with other subtype-B strains. Without treatment, advanced HIV—CD4 cell counts below 350 cells per cubic millimeter, with long-term clinical consequences—is expected to be reached, on average, 9 months after diagnosis for individuals in their thirties with this variant. Age, sex, suspected mode of transmission, and place of birth for the aforementioned 109 individuals were typical for HIV-positive people in the Netherlands, which suggests that the increased virulence is attributable to the viral strain. Genetic sequence analysis suggests that this variant arose in the 1990s from de novo mutation, not recombination, with increased transmissibility and an unfamiliar molecular mechanism of virulence.
Anti-HIV Agents / therapeutic use, HIV Infections / immunology, Medical Microbiology - Radboud University Medical Center, Adult, Male, HIV-1/genetics, Genotype, Evolution, Anti-HIV Agents, HIV Infections/drug therapy, HIV Infections, Clinical Pharmacy - Radboud University Medical Center, Genome, Viral, Evolution, Molecular, SDG 3 - Good Health and Well-being, HIV Infections / transmission, 616, Humans, Internal Medicine - Radboud University Medical Center, Viral, Phylogeny, HIV-1 / pathogenicity, Netherlands, Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences, HIV Infections / virology, Genome, Virulence, Molecular, Viral Load, HIV Infections / drug therapy, CD4 Lymphocyte Count, [SDV] Life Sciences [q-bio], Anti-HIV Agents/therapeutic use, Mutation, HIV-1, Female, HIV-1 / genetics, HIV-1 / physiology, Radboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences
Anti-HIV Agents / therapeutic use, HIV Infections / immunology, Medical Microbiology - Radboud University Medical Center, Adult, Male, HIV-1/genetics, Genotype, Evolution, Anti-HIV Agents, HIV Infections/drug therapy, HIV Infections, Clinical Pharmacy - Radboud University Medical Center, Genome, Viral, Evolution, Molecular, SDG 3 - Good Health and Well-being, HIV Infections / transmission, 616, Humans, Internal Medicine - Radboud University Medical Center, Viral, Phylogeny, HIV-1 / pathogenicity, Netherlands, Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences, HIV Infections / virology, Genome, Virulence, Molecular, Viral Load, HIV Infections / drug therapy, CD4 Lymphocyte Count, [SDV] Life Sciences [q-bio], Anti-HIV Agents/therapeutic use, Mutation, HIV-1, Female, HIV-1 / genetics, HIV-1 / physiology, Radboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 64 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 1% |
